Skip to main content
Imtiaz Maliik, MD, Oncology, Merced, CA

ImtiazMaliikMD

Oncology Merced, CA

Gastrointestinal Cancer

Physician

Dr. Maliik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Maliik's full profile

Already have an account?

  • Office

    731 E. Yosemite Ave
    Ste B, PMB 325
    Merced, CA 95348
    Phone+1 909-223-2075

Education & Training

  • King Edward Medical University
    King Edward Medical UniversityClass of 1977

Awards, Honors, & Recognition

  • Shams-uz-Zaman medal Pakistan Society of Clinical Oncology, 2002
  • Distinguished Service Award Pakistan Society of Clinical Oncology, 2000
  • Award, Distinguished Investigator from a developing country Australian Cancer Society, 1992
  • Join now to see all

Publications & Presentations

Journal Articles

  • Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase II study  
    Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, et al, Cancer, 1/1/2013
  • A phase I study of capecitabine, irinotecan, celecoxib & radiation as neoadjuvant therapy of patients with locally advanced rectal cancer  
    Malik I, Hussein F, Bush D, et al, Am J Clin Oncol, 1/1/2010
  • Reduction of neutropenia and febrile neutropenia in colorectal cancer patients receiving pegfilgrastim with every-2-week chemotherapy  
    Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I, Clin Colorectal Cancer, 1/1/2010
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase 2, randomized, controlled study.
    Hecht JR, Pillai M, Gollard R, Dreiling L, Mo M, Malik I, Proc Am Soc Clin Oncol, 1/1/2009
  • Pegfilgrastim reduces the incidence of neutropenia in patients with locally advanced or metastatic colon cancer receiving chemotherapy administered every 2 weeks as fi...
    Malik I, Gollard R, Patel R, Tomita D, Dreiling L, Hecht, J, Support Care Cancer, 1/1/2007
  • Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis.
    Mitchell E, Hecht JR, Baranda J, Malik I, et al, Proc Am Soc Clin Oncol, 1/1/2007
  • Join now to see all

Lectures

  • Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase 2, randomized, controlled study. 
    Orlando, FL - 1/29/2009
  • Effectiveness of darbepoetin alpha administered every 3 weeks on clinical outcomes in patients with gastrointestinal cancer and chemotherapy induced anemia. 
    San Francisco, CA - 1/18/2006
  • Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. 
    Orlando, FL - 1/13/2005
  • Join now to see all